Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.

Sanofi is re-upping its social media-driven Data Design Diabetes Innovation Challenge contest, which last year kicked up a wealth of innovative ideas and buzz for the price of $200,000 in prize money and a few salaries.

Sanofi-Aventis US is rolling out a consumer campaign for its Lantus SoloStar pen aimed at getting people with type 2 diabetes to think differently about insulin, while Novo Nordisk revs up another racing-themed social media effort for its FlexPen.